Martin Reck, MD, PhD, on Dual Immunotherapy Plus Chemotherapy: A Better Way to Treat NSCLC Than Chemotherapy Alone?

Posted: Tuesday, June 22, 2021

Martin Reck, MD, PhD, of LungenClinic, discusses the clinical implications of phase III findings from the CheckMate 9LA trial, which showed that first-line nivolumab plus ipilimumab plus chemotherapy demonstrated more durable survival and benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer.